for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover   The Medical Letter
  [SJR: 0.142]   [H-I: 16]   [6 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
   Published by The Medical Letter, Inc Homepage  [1 journal]
  • Onexton Gel for Acne
    • Authors: admin
      Abstract: Date:  August 31, 2015 Issue #:  1476 Summary:  The FDA has approved another fixed combination of the antibiotic clindamycin phosphate and the oxidizing agent benzoyl peroxide (Onexton Gel 1.2%/3.75% – Valeant) for topical treatment of acne in patients ≥12 years old. Topical products containing the same drugs have been available for many years. Onexton Gel contains a new strength of benzoyl peroxide.
      PubDate: Wed, 12 Aug 2015 11:55:10 +000
       
  • A New Subcutaneous Immune Globulin (HyQvia) for Primary Immunodeficiency
    • Authors: admin
      Abstract: Date:  August 31, 2015 Issue #:  1476 Summary:  Immune globulin (IgG) has been available for administration intravenously once every 3-4 weeks or subcutaneously once daily, once weekly, or every 2 weeks for treatment of primary immunodeficiencies. Now the FDA has approved human immune globulin 10% with recombinant human hyaluronidase (HyQvia – Baxter) for subcutaneous administration only every 3-4 weeks in adults with these disorders. The IgG component of HyQvia is identical to Gammagard Liquid, which was approved in 2005 for IV administration and in 2011 for SC administration.
      PubDate: Wed, 12 Aug 2015 11:54:38 +000
       
  • Abuse-Deterrent Opioid Formulations
    • Authors: admin
      Abstract: Date:  August 31, 2015 Issue #:  1476 Summary:  Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Three available opioid formulations, OxyContin (Purdue), Embeda (Pfizer), and Hysingla ER (Purdue), now include claims of abuse deterrence in their package inserts.
      PubDate: Wed, 12 Aug 2015 11:54:07 +000
       
  • ReShape and Orbera - Two Gastric Balloon Devices for Weight Loss
    • Authors: admin
      Abstract: Date:  August 31, 2015 Issue #:  1476 Summary:  The FDA has approved the ReShape Integrated Dual Balloon System (ReShape Medical) and the Orbera Intragastric Balloon System (Apollo Endosurgery) for up to 6 months of use in adults with a BMI of 30-40 who have not been able to maintain weight loss with a weight loss program and, for ReShape, who have at least one obesity-related comorbidity. Both devices have been available in the European Union and elsewhere for years (20 years for Orbera). Three other devices, the LAP-Band, the Realize adjustable gastric band, and the Maestro Rechargeable System, are FDA-approved for long-term treatment of obesity.
      PubDate: Wed, 12 Aug 2015 11:53:19 +000
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015